Q1 Earnings Estimate for Zenas Biopharma Issued By Wedbush

Zenas Biopharma Inc (NASDAQ:ZBIO) – Equities researchers at Wedbush issued their Q1 2025 earnings estimates for Zenas Biopharma in a note issued to investors on Thursday, March 20th. Wedbush analyst M. Fan anticipates that the company will post earnings per share of ($1.09) for the quarter. Wedbush has a “Outperform” rating and a $35.00 price objective on the stock. Wedbush also issued estimates for Zenas Biopharma’s Q2 2025 earnings at ($1.11) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.02) EPS, FY2025 earnings at ($4.33) EPS, Q1 2026 earnings at ($1.14) EPS, Q2 2026 earnings at ($1.15) EPS, Q3 2026 earnings at ($1.07) EPS, Q4 2026 earnings at ($1.08) EPS and FY2026 earnings at ($4.43) EPS.

Separately, Guggenheim restated a “buy” rating and issued a $45.00 price objective on shares of Zenas Biopharma in a research note on Wednesday, March 12th.

Zenas Biopharma Trading Down 2.2 %

NASDAQ ZBIO opened at $8.33 on Monday. Zenas Biopharma has a 12 month low of $5.83 and a 12 month high of $26.25. The firm has a market capitalization of $348.19 million and a P/E ratio of -2.35.

Zenas Biopharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.